Lecanemab Gains FDA Approval for Early Alzheimer Disease.
JAMA. 2023.
PMID: 36652625
No abstract available.
Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2023 | 1 |
| 2025 | 1 |
Search Results
2 results
Results by year
Citations
1
article
found by citation matching
Search results
Filters applied: . Clear all
Page 1
Lecanemab Gains FDA Approval for Early Alzheimer Disease.
Larkin HD.
Larkin HD.
JAMA. 2023 Feb 7;329(5):363. doi: 10.1001/jama.2022.24490.
JAMA. 2023.
PMID: 36652625
No abstract available.
Item in Clipboard
Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective.
Bobbins A, Davies M, Lynn E, Roy D, Yeomans A, Shakir SAW.
Bobbins A, et al.
Br J Clin Pharmacol. 2025 May;91(5):1352-1360. doi: 10.1002/bcp.70021. Epub 2025 Mar 6.
Br J Clin Pharmacol. 2025.
PMID: 40051090
Free PMC article.
Review.
The development of humanized IgG1 anti-amyloid monoclonal antibodies, such as lecanemab, provides a promising novel treatment pathway with potential disease-modifying effects for patients with early Alzheimer's disease (AD). Lecanemab, wh …
The development of humanized IgG1 anti-amyloid monoclonal antibodies, such as lecanemab, provides a promising novel treatment pathway …
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.